Peptilogics

Peptilogics is an early stage biotech developing a breakthrough technology platform in the antimicrobial segment. The company's focus is on antibiotics for the treatment of Multidrug-resistant bacteria, or superbugs. Antibiotic resistance is recognized as a globally endemic concern. The company's eCAP technology has preclinical effectiveness against resistant bacteria and biofilms. The company is dedicated to developing a new class of broad-spectrum antibiotics to address the epidemic of multidrug-resistant bacterial infections.